The most popular article from the Managed Healthcare Executive® print publication was a pre-pandemic story about the top 6 challenges facing healthcare executives.
Of course COVID-19 garnered most of the headlines in 2020. But the best-read stories from our print publication (which are subsequently posted on the website) covered a range of topics, from drugs in the pipeline to pulse oximeters to the top challenges for healthcare executives.
Our predictions at the beginning of 2020 about the drugs headed for approval or sale. Reyvow (Lasmiditan), Adakveo (crizanlizumab-tmca) and Givlaari (givosiran) were on this pre-pandemic list.
At-home pulse oximeter purchases have spiked 500% in the months after COVID-19 pandemic hit the United States because the disease lowers oxygen levels. The American Lung Association sounded a cautious note, advising against buying the device unnecessarily.
The 2020 trends we looked at included a shift from hospital to ambulatory settings, consolidation across the sector and effort to protect data privacy.
Our story looked at limits on opioids, provisions in the Drug Supply Chain Security Act and pharmacists prescribing hormonal contraceptives.
COVID-19 overwhelmed every other challenges healthcare executives had in 2020. Our story in early January identified complying with new government regulations, a shift to value-based care and using big data as the hills that executives would be climbing in 2020.